Scarica l'app Stockscreener
2.44
3.94%
-0.10
Dopo l'orario di chiusura:
2.44
Precedente Chiudi:
$2.54
Aprire:
$2.42
Volume 24 ore:
78,026
Relative Volume:
0.85
Capitalizzazione di mercato:
$59.45M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-22.78%
1M Prestazione:
-44.42%
6M Prestazione:
-84.59%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.29
$2.53
Intervallo di 1 settimana:
$2.29
$3.31
Portata 52W:
$2.29
$17.31
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Nome
Artiva Biotherapeutics Inc
Settore
Industria
Telefono
(858) 267-4467
Indirizzo
5505 MOREHOUSE DRIVE, SAN DIEGO
Confronta ARTV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
2.44 | 59.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Iniziato | Jefferies | Buy |
| 2024-08-13 | Iniziato | Needham | Buy |
| 2024-08-13 | Iniziato | TD Cowen | Buy |
| 2024-08-13 | Iniziato | Wedbush | Outperform |
Mostra tutto
Artiva Biotherapeutics Inc Borsa (ARTV) Ultime notizie
Artiva Biotherapeutics Reports 2024 Financial Results - TipRanks
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year - Investing.com Canada
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Artiva Biotherapeutics’ SWOT analysis: NK cell therapy stock faces pivotal year By Investing.com - Investing.com South Africa
What is Wedbush’s Forecast for ARTV Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for ARTV Earnings - Defense World
Brokers Issue Forecasts for ARTV Q1 Earnings - Defense World
Artiva Biotherapeutics (NASDAQ:ARTV) Earns “Buy” Rating from HC Wainwright - Defense World
Cantor Fitzgerald Issues Negative Outlook for ARTV Earnings - Defense World
Artiva Biotherapeutics: Strong Buy Rating Backed by Promising Pipeline and Financial Stability - TipRanks
Artiva Biotherapeutics stock rises following analyst optimism By Investing.com - Investing.com South Africa
Artiva Biotherapeutics stock rises following analyst optimism - Investing.com
Artiva Biotherapeutics (NASDAQ:ARTV) Price Target Cut to $20.00 by Analysts at Cantor Fitzgerald - Defense World
Artiva Biotherapeutics’ (ARTV) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reaffirmed at Needham & Company LLC - Defense World
NK Cell Therapy Pipeline 2025: Key Developments, Emerging - openPR.com
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Artiva Biotherapeutics Reports Full Year 2024 Results and Updates on AlloNK® Autoimmune Program with Key Leadership Strengthening - Nasdaq
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors - Business Wire
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Allogeneic CAR-T Cell Patent Landscape and Forecast Report - GlobeNewswire
Allogeneic CAR-T Cell Patent Landscape and Forecast Report 2024-2032, Profiles of Artiva Biotherapeutics, Poseida Therapeutics, Nanjing Beiheng Biological Technology, NantCell, GC Cell, BMS, Compugen - Yahoo Finance
Rhumbline Advisers Has $130,000 Position in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics (ARTV) Expected to Announce Earnings on Tuesday - Defense World
My Favorite "Magnificent Seven" Stock Just Joined the Quantum Computing Revolution (Hint: It's Not Nvidia) - The Globe and Mail
Nk Cell Therapy Pipeline 2024: FDA Updates, Therapy - openPR
Autodesk Designs Value for Investors: Uptrend Set to Continue - The Globe and Mail
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight - GlobeNewswire Inc.
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Financial Comparison: Compugen (NASDAQ:CGEN) & Artiva Biotherapeutics (NASDAQ:ARTV) - Defense World
Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm - Citeline News & Insights
JPMorgan Chase & Co. Buys New Holdings in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran - MSN
Artiva Biotherapeutics appoints new director and committee members - Investing.com India
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - GlobeNewswire
Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan
Natural killer cells, a rising alternative to CAR-T cell therapy - PharmaVoice
Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $21.00 - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Artiva Biotherapeutics Inc Azioni (ARTV) Dati Finanziari
Non sono disponibili dati finanziari per Artiva Biotherapeutics Inc (ARTV). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):